Century Therapeutics (NASDAQ:IPSC) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Century Therapeutics (NASDAQ:IPSC) from a hold rating to a sell rating in a research report report published on Monday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $3.75.

Century Therapeutics Trading Up 5.2%

Shares of IPSC opened at $0.57 on Monday. The business’s fifty day simple moving average is $0.52 and its two-hundred day simple moving average is $0.54. Century Therapeutics has a 12 month low of $0.34 and a 12 month high of $1.83. The company has a market cap of $49.28 million, a price-to-earnings ratio of -1.97 and a beta of 1.78.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Thursday, August 14th. The company reported ($0.38) EPS for the quarter, meeting the consensus estimate of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. As a group, research analysts forecast that Century Therapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Century Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of IPSC. Bank of America Corp DE lifted its position in Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after purchasing an additional 34,466 shares in the last quarter. Nuveen LLC purchased a new position in Century Therapeutics during the first quarter valued at $75,000. AQR Capital Management LLC lifted its position in Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after purchasing an additional 86,875 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Century Therapeutics by 26.9% during the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after purchasing an additional 38,052 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Century Therapeutics by 101.2% during the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after purchasing an additional 142,953 shares in the last quarter. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.